# Lupus Nephritis: Activity, Chronicity, and Long-Term Care

Biopsy activity and protein/kidney-function trends guide treatment; serology, class, and chronicity inform the decision but never supply a guaranteed prognosis.

![Infographic: Lupus Nephritis: Activity, Chronicity, and Long-Term Care](https://urinenephrology.org/visual-reference/images/lupus-nephritis.png?v=20261003c)

## Detect kidney involvement

In SLE, follow creatinine/eGFR, urinalysis, and urine protein alongside BP and symptoms. New proteinuria, glomerular hematuria, or unexplained declining function requires assessment even if joint/skin disease is quiet. Complement and anti-dsDNA trends support evaluation but cannot diagnose a flare alone.

## Decide when biopsy changes care

KDIGO uses proteinuria around ≥500 mg/day as a threshold to consider biopsy, with active sediment or unexplained falling function also important. Lesser proteinuria can still accompany active disease. Biopsy class, activity, chronicity, and vascular lesions guide treatment.

## Active class III/IV ± V

Initial treatment combines glucocorticoids with a mycophenolic-acid regimen, low-dose IV cyclophosphamide, or appropriate combination therapy including belimumab or a CNI. Select according to severity, kidney function, fertility/pregnancy plans, infection risk, access, and the specific evidence—not class alone.

## Pure class V differs

Low-level proteinuria often emphasizes supportive care and treatment of extrarenal lupus. Nephrotic proteinuria or its complications may justify immunosuppression. CNI trial eligibility and product precautions matter; an eGFR exclusion from one trial is not a universal contraindication to every CNI.

## Measure renal response

Follow urine protein and kidney function serially, with BP, sediment, adherence, and toxicity. A common complete-response benchmark is protein <0.5 g/g with stable/improved kidney function, often assessed over 6–12 months; some patients respond later. This is not a guaranteed individual timetable.

## Plan the long course

Use hydroxychloroquine unless contraindicated, plus indicated BP/proteinuria protection. Coordinate maintenance therapy, contraception or pregnancy planning, vaccination/infection prevention, and bone care. Unexpected worsening prompts assessment for nonadherence, infection, thrombosis, toxicity, or persistent activity; repeat biopsy can clarify.

## Supporting evidence

- [Supporting guideline or source](https://kdigo.org/wp-content/uploads/2024/01/KDIGO-2024-Lupus-Nephritis-Guideline.pdf)
- [Supporting guideline or source](https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/acr.25528)

## Source lessons

- [SLE](https://urinenephrology.org/2025_UDPA_Lectures_Live/glomerulonephritis/SLE.html)
- [case7 enhanced](https://urinenephrology.org/2025_UDPA_Lectures_Live/cases/case7_enhanced.html)

Read alongside the full lessons; the findings and decisions shown here require the stated clinical context.